GO
Loading...

Valeant Pharmaceuticals International Inc

More

  • Valeant slashes stake in Allergan after losing bid Thursday, 20 Nov 2014 | 7:14 PM ET

    Nov 20- Valeant Pharmaceuticals International Inc said it cut its stake in Allergan Inc to 0.1 percent from 9.7 percent, three days after Actavis Plc trumped its offer for the Botox maker. Pershing Square Capital Management informed Valeant that PS Fund 1 sold all of its 2.2 million shares in Allergan allocated to Valeant USA, Valeant said in a regulatory filing.

  • Nov 20- Canada's Valeant Pharmaceuticals International Inc said it may buy back up to $2 billion worth of securities, replacing a previous $1.5 billion program under which it bought back no securities. The announcement comes a few days after acquisition-hungry Valeant's $54 billion offer to buy Botox maker Allergan Inc was trumped by Actavis Plc's $66...

  • Mega-mergers are popular again on Wall Street Tuesday, 18 Nov 2014 | 6:47 AM ET

    Deals worth $100 billion on Monday put the Street on pace for a year rivaling the dot-com bubble era and the private equity surge just before the financial crisis.

  • Hedge funds ditch Apple for AbbVie and Alibaba Tuesday, 18 Nov 2014 | 5:29 AM ET
    A couple look at an Apple Inc. iPhone 6 at an Apple store in the China Central Mall in Beijing, China, on Tuesday, Nov. 11, 2014.

    Hedge funds flocked to Apple ahead of launch of the iPhone 6, but the company is now the most sold position among some of world's largest funds.

  • Cramer: The lucrative journey of Allergan Monday, 17 Nov 2014 | 6:07 PM ET
    A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan Inc.

    Jim Cramer reviews the acquisition of Allergan by Actavis to judge just how lucrative the deal could really be for shareholders.

  • Halliburton and Allergan are big market movers Monday, 17 Nov 2014 | 4:33 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. Halliburton Co., down $5.85 to $49.23. The Botox maker is being bought by Actavis for $66 billion, which tops a bid made by Valeant Pharmaceuticals last spring.

  • Nov 17- Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc.. Besides the higher price tag, the Actavis deal came with only $400 million in R&D cuts for Allergan, far less than the $900 million decrease...

  • NEW YORK, Nov 17- Actavis will issue around US $27.5 bn of new debt to finance its US $66 bn acquisition of Botox-maker Allergan, but about half of it will be short-dated to help the company keep its investment-grade ratings. Both Moody's and Fitch said they would not downgrade Actavis to junk despite the increased debt, believing strong cash flow will enable it to...

  • Losing Allergan deals blow to Valeant reputation Monday, 17 Nov 2014 | 1:25 PM ET

    WINNIPEG/ NEW YORK Nov 17- The failure of Valeant Pharmaceuticals International Inc to buy Allergan Inc leaves it with nothing to show for a seven-month, bruising pursuit. Losing Allergan to Actavis PLC also hurts Valeant's deal-making reputation, said a source close to the company not authorized to speak publicly. Allergan's rebuff will embolden future...

  • Done deal: Actavis buying Allergan for $66 billion Monday, 17 Nov 2014 | 11:55 AM ET
    Actavis pharmaceuticals.

    The deal beats the unsolicited bid last spring of above $50 billion from Valeant, which teamed with Bill Ackman.

  • Nov 17- Allergan Inc agreed to be bought by Actavis Plc for $66 billion, putting an end to a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc.. The offer values Allergan at $219 per share and is $6 billion more than the price Valeant had last offered to pay. Allergan shares rose 6.6 percent to $211, earning Ackman a...

  • Nov 17- Valeant Pharmaceuticals International Inc Chief Executive Michael Pearson said on Monday that the company can't justify matching Actavis Plc's $219 per share bid for Allergan Inc..

  • Actavis to spend $66 billion on Allergan Monday, 17 Nov 2014 | 9:32 AM ET

    Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products. Actavis and the company it outbid for Allergan, Valeant Pharmaceuticals, both have grown rapidly in recent years through multibillion dollar acquisitions of other drugmakers.

  • Allergan agrees to Actavis deal for $66 billion Monday, 17 Nov 2014 | 9:20 AM ET

    Nov 17- Allergan Inc agreed to be bought by Actavis Plc for $66 billion, more than $12 billion above the current value of a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc. The offer values Allergan at $219 per share, compared with its Friday close of $198.65. Valeant's latest cash-and-stock offer is currently...

  • Ahead of the Bell: Allergan soars on deal reports Monday, 17 Nov 2014 | 7:38 AM ET

    Shares of Allergan jumped in premarket trading Monday after several reports surfaced over the weekend that specialty drugmaker Actavis was preparing to buy the Botox maker, which is fighting off a separate takeover bid from Valeant Pharmaceuticals. The New York Times reported that Allergan is nearing a deal to sell itself to Actavis for more than $62.5...

  • Nov 16- Allergan Inc is close to a buyout deal worth up to $65.5 billion by Actavis Plc, one that could end months of pursuit by Canada's Valeant Pharmaceuticals and William Ackman's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter. Actavis may pay Allergan between $215 and $220 per share, with the final price likely...

  • BUSINESS-NEWS-SCHEDULE AT 2200 GMT / 5 PM ET Sunday, 16 Nov 2014 | 4:46 PM ET

    WASHINGTON- President Barack Obama defends the transparency of his signature healthcare law after a White House adviser on the reform said the law passed, in part, because of the "stupidity" of American voters. ALLERGAN, ACTAVIS NEAR DEAL, ANNOUNCEMENT AS EARLY AS MONDAY. NEW YORK- Allergan nears a deal to merge with Actavis Plc, with an announcement coming as soon as...

  • Nov 16- Allergan Inc is near a deal to merge with Actavis Plc, with an agreement to be announced as soon as Monday, according to a person familiar with the matter. Actavis is likely to pay Allergan between $210 and $220 per share, according to the source. Actavis and Allergan declined to comment.

  • Actavis nears rescue bid for Allergan: Sources Sunday, 16 Nov 2014 | 2:52 PM ET

    Actavis is nearing a deal to acquire Allergan in a cash and stock deal worth more than $210 per Allergan share, sources tell CNBC.

  • Are you an investing chicken? Check out these funds Friday, 14 Nov 2014 | 10:14 AM ET

    Scared of the stock market? These are a few investments that won't make you even more of a coward than you are. USA Today reports.